{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.92","value":"76.2"},{"groupId":"OG001","spread":"15.97","value":"77.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"884"},{"groupId":"OG001","value":"439"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.19","value":"74.7"},{"groupId":"OG001","spread":"16.79","value":"74.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"840"},{"groupId":"OG001","value":"419"}],"units":"Participants"}],"title":"Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.69","value":"74.6"},{"groupId":"OG001","spread":"17.51","value":"74.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"738"},{"groupId":"OG001","value":"342"}],"units":"Participants"}],"title":"Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.02","value":"74.7"},{"groupId":"OG001","spread":"18.28","value":"73.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"635"},{"groupId":"OG001","value":"250"}],"units":"Participants"}],"title":"Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.79","value":"74.5"},{"groupId":"OG001","spread":"17.11","value":"73.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"536"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"title":"Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.06","value":"75.5"},{"groupId":"OG001","spread":"16.82","value":"73.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"435"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Week 81"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.39","value":"74.4"},{"groupId":"OG001","spread":"17.88","value":"75.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"365"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"title":"Week 97"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.05","value":"73.6"},{"groupId":"OG001","spread":"15.06","value":"74.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"title":"Week 113"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.25","value":"72.8"},{"groupId":"OG001","spread":"12.83","value":"77.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"Week 129"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.02","value":"75.3"},{"groupId":"OG001","spread":"18.13","value":"74.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Week 145"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.28","value":"74.6"},{"groupId":"OG001","spread":"17.60","value":"73.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Week 161"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.31","value":"74.5"},{"groupId":"OG001","value":"69.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Week 177"}],"denoms":[{"counts":[{"groupId":"OG000","value":"933"},{"groupId":"OG001","value":"468"}],"units":"Participants"}],"description":"EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ VAS. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 4 capsules of Enzalutamide 40 mg each (total dose 160 mg per day) orally, once daily in double-blind and open-label phase (up to a maximum of 68.8 months) until radiographic progression. Participants after last dose of study drug, were followed up for safety up to 30 days, and were long term followed up (for survival status and new prostate cancer therapies) from last dose to the death date or last known survival date.","id":"OG000","title":"Enzalutamide 160 mg"},{"description":"Participants received 4 capsules of placebo (matched to Enzalutamide) orally, once daily in double blind phase (up to a maximum of 51.3 months) until radiographic progression. Participants were given an opportunity to switch to open-label enzalutamide after completion of double blind phase. Participants after last dose of study drug, were followed up for safety up to 30 days and were long term followed up (for survival status and new prostate cancer therapies) to the death date or last known survival date.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"The ITT population was defined as all participants randomly assigned to study treatment and was based on randomized treatment assignment regardless of whether or not treatment was administered. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 17, 33, 49, 65, 81, 97, 113, 129, 145,161 and 177","title":"European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Overall Health Status Visual Analog Score (VAS)","type":"SECONDARY","unitOfMeasure":"units on a scale"}